Postoperative Restrictive Opioid Protocols, Changes in Opioid Prescribing, Chronic Use

JAMA Oncology

EMBARGOED FOR RELEASE: 11 A.M. (ET), THURSDAY, JANUARY 5, 2023

Media advisory: The full study is linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jamaoncology/fullarticle/10.1001/jamaoncol.2022.6278?guestAccessKey=a621554c-d2a3-4f1a-88cf-1e17713d89f6&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=010523

 

About The Study: Implementation of a restrictive opioid prescription protocol specifying an opioid supply of three or fewer days was feasible and no compromises in patient recovery were detected in this study of 4,000 surgical patients in a large tertiary cancer center. The change led to a significant reduction in opioids dispensed postoperatively and was associated with significantly decreased conversion to chronic opioid use in postsurgical patients. 

Authors: Emese Zsiros, M.D., Ph.D., of the Roswell Park Comprehensive Cancer Center in Buffalo, New York, is the corresponding author. 

 

(doi:10.1001/jamaoncol.2022.6278)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.